JP2006265188A - Preparation set for permanent wave processing agent and method for preparing permanent wave processing agent using the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a first agent preparation set for a two-part permanent wave processing agent avoiding problems in stability of a cyclic mercapto compound in the presence of water with time because the first agent for the two-part permanent wave processing agent can be prepared by filling a container with the specific cyclic mercapto compound and a diluting agent containing the water out of contact with the cyclic mercapto compound as the separate agents, respectively and mixing the agents in use. <P>SOLUTION: The first agent preparation set for the two-part permanent wave processing agent is composed of a reducing agent-containing agent containing the specific cyclic mercapto compound and the diluting agent containing water. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a preparation set for a permanent wave processing drug, a method for preparing a permanent wave processing drug using the same, and a permanent wave processing method.

  It is known that a permanent wave is formed by two processes. That is, there are a step of reducing and cleaving the cystine (disulfide) bond of hair by the action of the reducing agent, and a subsequent neutralization or fixing step using an oxidizing agent, and the latter step restores the cystine (disulfide) bond.

  Conventionally, compounds generally used as keratin reducing substances such as thioglycolic acid, cysteine, acetylcysteine, and salts thereof have been used as compounds used in permanent processing of hair. Since these conventional compounds, which are also called keratin reducing substances, have practical performance under alkaline conditions for the permanent processing of hair, many permanent liquids are adjusted to be alkaline with a pH of about 9.5. However, it is known that perm liquid adjusted to alkaline causes damage to hair and scalp, and in order to solve these disadvantages, a neutral to slightly acidic pH range (pH: 3 to 7.5, 25). The development of keratin reducing substances that can be used at 0 ° C is underway.

For example, use of a monoglycerol ester of thioglycolic acid as a keratin reducing substance used in such a pH range has been studied (for example, Patent Document 1). In addition, the use of mercaptoglycolamide derivatives and mercaptolactic acid amide derivatives has also been studied for the purpose of solving skin disorders observed with thioglycolate esters (for example, Patent Document 2 and Patent Document 3). Furthermore, the use of cysteamine, which is considered to be effective with weak acidity, has also been studied. (For example, Patent Document 4)
Japanese Patent Application Laid-Open No. 08-291031 Special Table 2000-507272 Special table 2003-528901 gazette JP 03-271214 A

  However, the thioglycolic acid monoglycerol ester proposed in Patent Document 1 is in a liquid state and is excellent in terms of handleability and odor, but there is also a report of sensitization presumed to be derived from a hydroxyl group in the structure. It has not reached.

  The mercaptocarboxylic acid amide proposed in Patent Document 2 is already known to have skin irritation, and the same sensitization is also a concern with the mercaptocarboxylic acid amide derivative proposed in Patent Document 3, Furthermore, there is a problem that there is a concern about lack of purification, sensitization by raw material amine released during storage, and skin irritation.

The cysteamine proposed in Patent Document 4 does not have sufficient wave performance from weak acidity to acidity, and there are many problems such as the hair after perm treatment has a unique odor.
As described above, in the conventional keratin reducing substances, the desired permanent wave processing chemicals have not always been obtained.

  As a solution to this problem, the present applicant has already proposed a permanent wave processing agent containing a cyclic mercapto compound represented by the formula (1) or the like as a keratin-reducing substance. This permanent waving agent has higher wave performance than known compounds in a neutral to weakly acidic pH range where there is little irritation to hair and skin, while reducing irritation to hair and skin. Wave processing can be reliably applied to the hair.

  However, the stability of the cyclic mercapto compound in an aqueous solution is not sufficient, and there is room for improvement. For example, when a composition containing the cyclic mercapto compound and water is prepared in advance as a first agent for a two-part permanent wave processing agent, the cyclic mercapto compound decomposes over time, In addition to a decrease in the mercapto compound concentration over time, there is a problem in that coloring, precipitation, and the like occur with decomposition, thereby deteriorating the appearance and reducing the commercial value.

  For this reason, the present invention avoids the problem of stability over time in the presence of water, and reliably prepares the first agent of a two-part permanent wave processing agent containing the above-mentioned specific cyclic mercapto compound. The purpose is to provide a set agent that can be used.

  As a result of intensive research, the present inventors filled the container with the specific cyclic mercapto compound as a separate agent without bringing it into contact with water, and mixed them in the event of using two agents. It has been found that the preparation of the first agent of the chemical permanent wave processing agent can avoid the problem of stability with time of the cyclic mercapto compound in the presence of water, and the present invention has been completed.

That is, the present invention includes the following items [1] to [11].
[1] A first agent of a two-part permanent wave processing agent comprising a reducing agent-containing agent containing a compound represented by the following formula (1) and a diluting agent containing water Preparation set;

(X represents a structure of any of —O—, —S—, —NH—, and —NR ¹ —. R ¹ represents an alkyl group having 1 to 6 carbon atoms. R ² represents a hydrogen atom or 1 carbon atom. Represents an alkyl group of ˜6, Y represents an oxygen atom or a sulfur atom, and R represents a divalent organic residue which may have a mercapto group.

  [2] The reducing agent-containing drug according to [1], wherein the reducing agent-containing drug contains an organic solvent in addition to the compound represented by the formula (1). Agent preparation set.

[3] The two-component permanent wave according to [1] or [2], wherein X in the formula (1) is —O—, —NH—, —NCH ₃ — or —S—. First of processing chemicals
Agent preparation set.

[4] The first agent preparation set for a two-part permanent waving agent according to any one of [1] to [3], wherein Y in the formula (1) is an oxygen atom.
[5] The first agent preparation set for a dual agent permanent wave processing agent according to any one of [1] to [4], wherein R in the formula (1) is an alkylene group.

  [6] The agent for permanent drug processing according to any one of [1] to [4], wherein R in the formula (1) is an alkylene group having one or more mercapto groups First agent preparation set.

[7] The compound represented by the formula (1) is
At least one selected from the group consisting of 2-mercapto-4-butyrolactone, 2-mercapto-4-methyl-4-butyrolactone, 2-mercapto-4-ethyl-4-butyrolactone and 2-mercapto-6-hexanolactam The first agent preparation set for a two-part permanent wave processing agent according to [1] or [2], wherein

  [8] The reducing agent-containing drug according to any one of the above [1] to [7] and the dilution drug are mixed in advance before being applied to the hair, and the first agent of the two-component permanent wave processing drug A method for preparing a first agent for a two-part permanent wave processing agent, characterized in that:

[9] A permanent wave processing method for hair, comprising using the first agent preparation set for the two-component permanent wave processing agent according to any one of [1] to [7].
[10] The first agent preparation set for the two-part permanent wave processing agent according to any one of [1] to [7] and the second agent for the two-part permanent wave processing agent containing an oxidizing agent The preparation set of the chemical | medical agent for 2 agent type permanent wave processing characterized by these being comprised.

  [11] A permanent waving method for hair, comprising using the preparation set for a two-component permanent waving agent described in [10] above.

  According to the first agent preparation set of the two-component permanent wave processing agent of the present invention, the specific cyclic mercapto compound is filled in a container as a separate agent without contacting with water, These can be mixed together to prepare the first agent of the two-component permanent wave processing agent, so that the problem of stability with time of the cyclic mercapto compound in the presence of water can be avoided.

  Further, when the reducing agent-containing drug of the first agent preparation set of the two-part permanent wave processing agent of the present invention contains an organic solvent in addition to the specific cyclic mercapto compound, the entire reducing agent-containing drug Since the surface tension of the container is improved, it is possible to prevent the component from adhering to the inner wall of the container filled with the reducing agent-containing drug, and even if the reducing agent-containing drug adheres to the inner wall of the container, Since the amount of the mercapto compound is diluted with an organic solvent, the residual amount of the cyclic mercapto compound can be reduced. Therefore, the cyclic mercapto compound in the first agent of the two-part permanent wave processing agent to be finally obtained The density can be adjusted easily and reliably.

Hereinafter, the present invention will be specifically described.
<First agent preparation set for two-component permanent wave processing agent>
The first agent preparation set for the two-component permanent wave processing agent of the present invention is composed of a reducing agent-containing agent containing a cyclic mercapto compound represented by the following formula (1) and a diluting agent containing water. It is characterized by that.

≪Reducing agent-containing drug≫
Cyclic Mercapto Compound The reducing agent-containing drug used in the present invention contains at least a cyclic mercapto compound represented by the following formula (1).

In the above formula (1), X is -O -, - S -, - NH -, - NR 1 - shows the structure of any of, R ¹ represents an alkyl group having 1 to 6 carbon atoms. R ² represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms. Y represents an oxygen atom or a sulfur atom. R represents a divalent organic residue which may have a mercapto group.

As R ¹ , a methyl group or an ethyl group is desirable from the viewpoint of improving permeability to hair. More preferably, R ¹ is a methyl group.
X is preferably —O—, —NH—, —NCH ₃ — or —S— from the viewpoint of the solubility in a diluent containing water, which will be described later.

In the formula (1), Y represents an oxygen atom or a sulfur atom, and an oxygen atom is more preferable from the viewpoint of industrial raw material availability and handleability.
Examples of R ² include a hydrogen atom, a methyl group, an ethyl group, and a propyl group. Among them, a hydrogen atom, a methyl group, and an ethyl group are preferable.

R represents a divalent organic residue which may have a mercapto group (-SH). R is not particularly limited as long as it is a divalent organic group, but is preferably an alkylene group. As the alkylene group, an alkylene group having 2 to 6 carbon atoms in the main chain is preferable. Moreover, you may have a branch and / or a side chain. Examples of the side chain include an alkyl group and an alkenyl group.

  Moreover, when R has a mercapto group, the mercapto group may be one or plural, but one or two is preferable. In particular, the divalent organic residue is preferably one having a mercapto group bonded to an alkylene group. Moreover, there is no restriction | limiting in particular in the position which a mercapto group couple | bonds with an alkylene group. The mercapto group may be directly bonded to the alkylene group, or may be further via an alkylene group (for example, a mercaptoethyl group).

Among these, preferable R includes an ethylene group and a propylene group in terms of industrial availability.
Specific examples of the compound represented by the formula (1) include 2-mercapto-3-propiolactone, 2-mercapto-2-methyl-3-propiolactone, 2-mercapto-3-methyl-
3-propiolactone, 2-mercapto-3-ethyl-3-propiolactone, 2-mercapto-2,3-dimethyl-3-propiolactone, 2-mercapto-3-propiolactam, 2-mercapto- 2-Methyl-3-propiolactam, 2-mercapto-3-methyl-3-propiolactam, 2-mercapto-3-ethyl-3-propiolactam, 2-mercapto-2,3-dimethyl-3- Propiolactam, 2-mercapto-3-propiothiolactone, 2-mercapto-2-methyl-3-propiothiolactone, 2-mercapto-3-methyl-3-propiothiolactone, 2-mercapto-3 -Ethyl-3-propiothiolactone, 2-mercapto-2,3-dimethyl-3-propiothiolactone, 2-mercapto-4-butyrolac 2-mercapto-2-methyl-4,4-dimethyl-4-butyrolactone, 2-mercapto-3- (2-propenyl) -4-butyrolactone, 2-mercapto-4-methyl-4-butyrolactone, 2- Mercapto-2-methyl-4-butyrolactone, 2-mercapto-3-methyl-4-butyrolactone, 2-mercapto-4-methyl-4-butyrolactone, 2-mercapto-3,4-dimethyl-4-butyrolactone, 2- Mercapto-2-ethyl-4-butyrolactone, 2-mercapto-3-ethyl-4-butyrolactone, 2-mercapto-4-ethyl-4-butyrolactone, 2-mercapto-4-butyrothiolactone, 2-mercapto-2 -Methyl-4-butyrothiolactone,

2-mercapto-3-methyl-4-butyrothiolactone, 2-mercapto-4-methyl-4-butyrothiolactone, 2-mercapto-3,4-dimethyl-4-butyrothiolactone, 2-mercapto 2-ethyl-4-butyrothiolactone, 2-mercapto-3-ethyl-4-butyrothiolactone, 2-mercapto-4-ethyl-4-butyrothiolactone, 2-mercapto-4-butyrolactam, 2-mercapto-2-methyl-4-butyrolactam, 2-mercapto-3-methyl-4-butyrolactam, 2-mercapto-4-methyl-4-butyrolactam, 2-mercapto-3,4-dimethyl-4-butyrolactam, 2-mercapto-2-ethyl-4-butyrolactam, 2-mercapto-3-ethyl-4-butyrolactam, 2-mercapto-4 Ethyl-4-butyrolactam, 2-mercapto-5-valerolactone, 2-mercapto-2-methyl-5-valerolactone, 2-mercapto-3-methyl-5-valerolactone, 2-mercapto-4-methyl-5 -Valerolactone, 2-mercapto-5-methyl-5-valerolactone, 2-mercapto-2-ethyl-5-valerolactone, 2-mercapto-3-ethyl-5-valerolactone, 2-mercapto-4-ethyl -5-valerolactone, 2-mercapto-5-ethyl-5-valerolactone, 2-mercapto-5-valerolactam, 2-mercapto-2-methyl-5-valerolactam, 2-mercapto-3-methyl-5 -Valerolactam, 2-mercapto-4-methyl-5-valerolactam, 2-mercapto-5-methyl-5-vale Lactam, 2-mercapto-2-ethyl-5-valerolactam, 2-mercapto-3-ethyl-5-valerolactam,

2-mercapto-4-ethyl-5-valerolactam, 2-mercapto-5-ethyl-5-valerolactam, 2-mercapto-5-valerothiolactone, 2-mercapto-2-methyl-5-valerothiolactone, 2-mercapto-3-methyl-5-valerothiolactone, 2-mercapto-4-methyl-5-valerothiolactone, 2-mercapto-5-methyl-5-valerothiolactone, 2-mercapto-2-ethyl- 5-valerothiolactone, 2-mercapto-3-ethyl-5-valerothiolactone, 2-mercapto-4-ethyl-5-valerothiolactone, 2-mercapto-5-ethyl-5-valerothiolactone, 2- Mercapto-6-hexanolactone, 2-mercapto-2-methyl-6-hexanolactone, 2-mercapto-3-methyl 6-hexanolactone, 2-mercapto-4-methyl-6-hexanolactone, 2-mercapto-5-methyl-6-hexanolactone, 2-mercapto-6-methyl-6-hexanolactone, 2- Mercapto-6-hexanolactam, 2-mercapto-2-methyl-6-hexanolactam, 2-mercapto-3-methyl-6-hexanolactam, 2-mercapto-4-methyl-6-hexanolactam, 2-mercapto-5-methyl-6-hexanolactam, 2-mercapto-6-methyl-6-hexanolactam, 2-mercapto-6-hexanothiolactone, 2-mercapto-2-methyl-6-hexanothio Lactone, 2-mercapto-3-methyl-6-hexanothiolactone, 2-mercapto-4-methyl-6-hexanothiolactone, -Mercapto-5-methyl-6-hexanothiolactone, 2-mercapto-6-methyl-6-hexanothiolactone, 2-mercapto-7-heptanolactone, 2-mercapto-7-heptanothiolactone, 2-mercapto -7-heptanolactam, 2-mercapto-8-octanolactone, 2-mercapto-8-octanothiolactone, 2-mercapto-8-octanolactam, 2-mercapto-9-nonalactone, 2-mercapto-9 -Nonathiolactone, 2-mercapto-9-nonalactam, and N-methyl or N-ethyl derivatives of these lactams.

  Among these, 2-mercapto-4-butyrolactone (2-mercapto-4-butanolide), 2-mercapto-4-butyrothiolactone, 2-mercapto-4-butyrolactam, 2-mercapto-4-methyl-4- Butyrolactone, 2-mercapto-4-ethyl-4-butyrolactone, 2-mercapto-5-valerolactone, 2-mercapto-5-valerolactam, 2-mercapto-6-hexanolactam have permanent performance and industrial production. From the viewpoint of

  These compounds can be produced according to known methods. For example, it can be synthesized by introducing a mercapto group after using a lactone compound or a lactam compound as a halogenated compound.

  Specifically, mercaptolactone and mercaptothiolactone are commercially available using a commercially available lactone or thiolactone. Am. Chem. Soc. 1945,. 67. 2218-2220, a halogen compound synthesized by the method described in 67.2218-2220, or a commercially available halogen compound, is further used in Ann. A lactone derivative can be synthesized by reacting according to the method described in 1960, 639.146-56.

  Mercaplactams are described in J. Org. Am. Chem. Soc. 1958.80.6233-6237, using a halogen compound synthesized according to the method described in Ann. A lactam derivative can be synthesized by reacting according to the method described in 1960, 639.146-56.

  A permanent waving agent containing such a cyclic mercapto compound as a keratin-reducing substance acts at a low pH that does not affect the hair, exhibits a good waving effect, and has little effect on the skin. Although the reason for this is not clear, having the structure of the compound increases lipophilicity compared to conventional reducing agents, improves the permeability to hair, and has a heterocyclic ring to provide the cyclic mercapto compound. Is likely to be oxidized, in particular, neutral and weakly acidic and more easily oxidized. As a result, unlike mercapto compounds conventionally used, it is considered that the compound functions as a reducing agent without being alkaline.

However, such a cyclic mercapto compound tends to undergo a decomposition reaction over time in the presence of water.
For this reason, in the present invention, until the specific cyclic mercapto compound is not brought into contact with water until just before use, each of them is filled in separate containers as separate agents, and these are contacted for the first time when used. To prepare a first agent of a two-component permanent wave processing agent. By forming the first agent in the form of a multi-drug type set of such a business preparation type, the generation time of the decomposition reaction between the cyclic mercapto compound and water is delayed as much as possible, and the concentration of the cyclic mercapto compound is reduced. It can suppress and can exhibit the wave processing effect with respect to hair more effectively.

Organic solvent The reducing agent-containing drug preferably further contains an organic solvent in addition to the cyclic mercapto compound represented by the formula (1).

  The cyclic mercapto compound is an oily liquid at room temperature and can be used alone as a reducing agent-containing drug.However, since the surface tension is low compared to water, when this is filled alone in a container, The wettability with respect to the inner wall of the container is too good, and when the container is taken out of the container for mixing with a diluting agent described later, an adhesion residue may be seen in the container. Since the adhesion residue in the container cannot be blended in the first agent of the finally obtained two-component permanent wave processing agent, the concentration of the cyclic mercapto compound in the first agent is consequently reduced. There is a risk that the expected value may not be reached and the wave processing effect on the original hair cannot be fully achieved.

  In this case, the adhesion residue in the container can be taken out by washing several times with a diluting agent, which will be described later, and the necessary amount of the cyclic mercapto compound can be added to the first agent. Since it is complicated and not convenient, it is not practically preferable.

On the other hand, when the reducing agent-containing drug is mixed with an organic solvent in addition to the cyclic mercapto compound, the surface tension of the entire reducing agent-containing drug is improved. It is possible to prevent components from adhering to the inner wall of the container, and even if a reducing agent-containing drug adheres to the inner wall of the container, the amount of cyclic mercapto compound in the residual residue is diluted with an organic solvent. Since the residual amount of the compound can be reduced, the concentration of the cyclic mercapto compound in the first agent of the final two-agent permanent wave processing agent can be easily and reliably adjusted. Includes organic solvents that can dissolve the cyclic mercapto compound and can be used in cosmetics. Especially, the organic solvent which does not contain water substantially is used preferably. Here, the organic solvent substantially free of water means an organic solvent in which moisture contained unavoidably is reduced as much as possible by performing a distillation operation or a drying treatment with a desiccant.

  Specifically, ethanol, propanol, isopropanol, n-butanol, tert-butanol, propylene glycol, 1,2-pentanediol, 1,2-hexanediol, isopentyldiol, phenoxyethanol, dipropylene glycol, 3-methoxy- 3-propanol, 1,3-butanediol, 3-methyl-1,3-butanediol, glycerin, diglycerin, polyglycerin, polyethylene glycol, polypropylene glycol, ethyl carbitol, benzyl alcohol, benzyloxyethanol, ethoxyethanol, 2-methylpyrrolidone, 4-butyrolactone, 5-caprolactone, PEG400, polysorbate 20, 1,2-dimethoxyethane, diethylene glycol dimethyl ether, trie Tylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol diethyl ether, ethylene glycol monobutyl ether, acetone, α-amylcinnamaldehyde, almond oil, isoeugenol, isopropylmethylphenol, γ-undecalactone, eugenol, octyldodecanol, oleyl Alcohol, cocoa oil, cinnamon alcohol, methyl cinnamate, ethyl cinnamate, geraniol, isoamyl acetate, ethyl acetate, cinnamyl acetate, tocopherol acetate, phenylethyl acetate, butyl acetate, benzyl acetate, cyclohexane,

Citronellol, citronellal, squalane, stearyl alcohol, soybean oil, camellia oil, decylaldehyde, tocopherol, γ-nanolactone, liquid paraffin, castor oil, lanolin acetate, diglyceryl triisostearate, propylene glycol dicaprate, tetra-2-ethylhexanoic acid Pentaerythritol, propylene glycol monocaprylate, propylene glycol dicaprylate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, glyceryl tri-2-ethylhexanoate, 2-butyl-2-ethylhexanoate Ethyl-1,3-propanediol, butyl myristate, butyl stearate, cetyl isooctanoate, diethyl sebacate, diisopropiate adipate , Diisopropyl sebacate, diisostearyl malate, ethyl olive ethylene acid, isostearic acid 2-hexyl decyl myristate, 2-hexyldecyl stearate, 2-hexyldecyl, 2-ethylhexyl palmitate,

Isopropyl isostearate, isopropyl myristate, ethyl linoleate, isopropyl linoleate, glycerin monooleyl ether, hexamethyltetracosane, hexamethyltetracosanehexaene, hydrogenated polydecene, cyclic silicone / polymethylsiloxane / crosslinked methylpolysiloxane Mixture, castor oil / succinic acid / isostearic acid condensate, castor oil / succinic acid / isostearic acid condensate and nonionic surfactant, castor oil / succinic acid / isostearic acid / cationic surfactant condensation , Castor oil, succinic acid, isostearic acid, cationic surfactant condensate and nonionic surfactant, hydrogenated lecithin, 50% glycerin solution of hydroxylated lecithin, hydrogenated resorcin, glyceryl monoundecylenate , Glyceryl noisostearate, glyceryl dioleate, diglyceryl monooleate, diglyceryl dioleate, diglyceryl triisostearate, tetraglyceryl monooleate, tetraglyceryl pentaoleate, hexaglyceryl monolaurate, hexaglyceryl monomyristate, mono Hexaglyceryl oleate, hexaglyceryl pentaoleate, hexaglyceryl polyricinoleate, decaglyceryl monolaurate, decaglyceryl monoisostearate, decaglyceryl monooleate, decaglyceryl monolinoleate, decaglyceryl diisostearate, decaglyceryl trioleate , Decaglyceryl pentaisostearate, decaglyceryl pentaoleate, decaglyceryl heptaoleate , Decaisostearate decaglyceryl, dekaleic acid decaglyceryl, decamacademia nut oil fatty acid decaglyceryl, polyricinoleic acid decaglyceryl, monooleic acid POE (5) glyceryl (hereinafter, polyoxyethylene is also referred to as POE), monooleic acid POE (15) Glyceryl, sorbitan monolaurate, sorbitan monoisostearate, sorbitan sesquiisostearate, sorbitan monooleate, sorbitan sesquioleate, sorbitan trioleate, monococonut oil fatty acid POE (20) sorbitan, monopalmitic acid POE (20) Sorbitan, monostearic acid POE (20) sorbitan, monostearic acid POE (6) sorbitan, monoisostearic acid POE (20) sorbitan, monoolein Acid POE (20) sorbitan, trioleic acid POE (20) sorbitan, monolauric acid POE (6) sorbit, tetraoleic acid POE (6) sorbit, tetraoleic acid POE (30) sorbit, tetraoleic acid POE (40) sorbit Tetraoleic acid POE (60) sorbit, POE lanolin, POE (5) lanolin alcohol,

POE (10) lanolin alcohol, POE (20) lanolin alcohol, POE (3) castor oil, POE (10) castor oil, POE (20) castor oil, POE (40) castor oil, POE (50) castor oil, POE (60) Castor oil, POE (5) hydrogenated castor oil, POE (10) hydrogenated castor oil, POE (20) hydrogenated castor oil, POE (30) hydrogenated castor oil, POE (40) hydrogenated castor oil, POE (50) Hydrogenated castor oil, POE (60) hydrogenated castor oil, POE (80) hydrogenated castor oil, POE (2) lauryl ether, POE (4.2) lauryl ether, POE (9) lauryl ether, POE (21) lauryl ether, POE (25) lauryl ether, POE (2) cetyl ether, POE (5,5) cetyl ether, POE (7) cetyl Ether, POE (10) cetyl ether, POE (15) cetyl ether, POE (20) cetyl ether, POE (23) cetyl ether, POE (25) cetyl ether, POE (30) cetyl ether, POE (40) cetyl ether , POE (2) stearyl ether, POE (4) stearyl ether, POE (20) stearyl ether, POE (2) oleyl ether, POE (7) oleyl ether, POE (10) oleyl ether, POE (15) oleyl ether, POE (20) oleyl ether, POE (50) oleyl ether, POE (5) behenyl ether, POE (10) behenyl ether, POE (20) behenyl ether, POE (30) behenyl ether, POE (2) alkyl ether, P E (4) alkyl ether,

POE (10) alkyl ether, POE (1) POP (4) cetyl ether (hereinafter, polyoxypropylene is also referred to as POP), POE (10) POP (4) cetyl ether, POE (1) POP (8) cetyl Ether, diPOE (8) oleyl ether sodium phosphate, diPOE (2) alkyl ether phosphoric acid, diPOE (4) alkyl ether phosphoric acid, diPOE (6) alkyl ether phosphoric acid, diPOE (8) alkyl ether Phosphoric acid, di-POE (10) alkyl ether phosphoric acid, tri-POE (4) lauryl ether phosphoric acid, tri-POE (5) cetyl ether phosphoric acid, trioleyl phosphoric acid, tri-POE (2) alkyl ether phosphoric acid, tri-POE (6) alkyl ether phosphate, tri-POE (8) alkyl ether phosphate, tri-P E (10) alkyl ether phosphoric acid, POE (5) oleic amide, polyethylene glycol monolaurate (10E.O.), polyethylene glycol monooleate (2E.O.), polyethylene glycol monooleate (6E.O. ), Polyethylene glycol monooleate (10E.O.), polyethylene glycol diisostearate, 1,1′-methylenebis (4-isocyanatocyclohexane) polypropylene glycol copolymer, oleyl sarcosine, POE (4) lauryl ether acetic acid, POE (10) Lauryl ether acetic acid, POE (3) tridecyl ether acetic acid, POE (7) tridecyl ether acetic acid, methyl polysiloxane, methyl phenyl polysiloxane and the like. These can be used alone or in combination of two or more. Among these, 2-methylpyrrolidone, 4-butyrolactone, propylene glycol are mixed with the below-described diluent agent and easily dissolved in the diluent agent when the first agent for permanent wave processing agent is prepared carefully. POE (30) hydrogenated castor oil, POE (5) oleic acid amide, and methylpolysiloxane are preferred.

  The organic solvent is preferably added to the reducing agent-containing drug in an amount of 25 to 95% by mass, more preferably 40 to 90% by mass, when the total amount of the organic solvent and the cyclic mercapto compound is 100% by mass. include. When the organic solvent is contained in such an amount in addition to the cyclic mercapto compound, the surface tension of the entire reducing agent-containing drug is improved, and the components adhere to the inner wall of the container filled with the reducing agent-containing drug. And residue can be prevented.

  As described above, the reducing agent-containing drug contains at least the cyclic mercapto compound represented by the formula (1), preferably the cyclic mercapto compound and the organic solvent. In the former case, the cyclic mercapto compound is used. The compound may be directly filled into the container as it is in the stock solution. In the latter case, the composition may be prepared by appropriately performing stirring, mixing, dissolution, heating, etc. by a generally known method, and then filled into the container. The composition may be prepared in the container to be filled at the same time as filling or after filling.

  The filling amount of the reducing agent-containing drug into the container is the first of the two-part permanent waving drug obtained by mixing the reducing agent-containing drug and the diluting drug according to the amount of the diluting drug used later. It is preferable to calculate and adjust in advance such that the concentration of the cyclic mercapto compound in the agent falls within a desired range.

Specifically, in the first agent of the dual agent permanent wave processing agent, the cyclic mercapto compound represented by the above formula (1) is preferably 0.2 to 30% in terms of thioglycolic acid reducing power, More preferably, the concentration of the cyclic mercapto compound in the reducing agent-containing drug and the usage amount of the reducing agent-containing drug are set in consideration of the amount of the diluent used as described later so that it is contained in an amount of 1 to 15%. It is preferable to adjust. If the concentration of the cyclic mercapto compound is within this range, the wave efficiency can be kept high without damaging hair and skin.

  If the thioglycolic acid reducing power is less than 0.2%, the performance as a permanent waving agent may not be obtained at all. On the other hand, if it exceeds 30%, the hair damage may increase due to promotion of extreme curly hair and partial peeling of the cuticle in the hair of Mongoloid races represented by black hair.

  The thioglycolic acid reducing power conversion is a notation of keratin-reducing substance concentration determined for each treatment in the permanent wave quality standard for quasi-drugs, and the following methods (I) to (III) Concentration measured according to the above.

Thioglycolic acid reducing power conversion (I) Take 10 mL of sample in a 100 mL volumetric flask and add purified water (hereinafter simply referred to as “water”) conforming to cosmetic raw material standards to make a total volume of 100 mL. Make a solution.

  (II) Take exactly 20 mL of the test solution, add 50 mL of water and 5 mL of 30% sulfuric acid, gently heat and boil for 5 minutes. After cooling, titrate with 0.1N iodine solution, and the amount of consumption is AmL (indicator: starch sample solution 3 mL).

(III) The obtained titration result is calculated as a thioglycolic acid content by the following formula.
Reducing substance content (as thioglycolic acid) (%) = 0.4606 × A
In addition, the permanent wave agent (curling agent) for cosmetics classification has a self-regulated value set by the Permanent Wave Industry Association, and the amount used is regulated by the same measurement method.

≪Dilute drug≫
The diluent for use in the present invention contains at least water. Water is preferably used because of its versatility as a solvent and ease of handling. The water that can be used for the drug for dilution is not particularly limited, but water that has undergone a purification process such as ion-exchanged water, distilled water, or purified water is preferred.

Water can be used so as to be contained in an amount of usually 30 to 100% by mass, preferably 65 to 98% by mass in 100% by mass of the drug for dilution.
In addition to water, the dilution agent includes, as other components, a pH adjusting agent, a swelling agent, a penetration enhancer, a surfactant, a buffering agent, an oil agent in an amount within a range not impairing the effects of the present invention. Thickeners, hair protecting agents, wetting agents, emulsifiers, fragrances, dyes, stabilizers, odor masking agents, ultraviolet absorbers and the like can be used.

  Examples of pH adjusters include inorganic acids such as hydrochloric acid and phosphoric acid, or inorganic acid salts such as disodium hydrogen phosphate and sodium dihydrogen phosphate; organic acids such as citric acid, malic acid, lactic acid, succinic acid, and oxalic acid. Or an alkali agent such as ammonia, diethanolamine, triethanolamine, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, or the like.

The pH adjuster mixes the diluting agent and the reducing agent-containing agent described above to obtain the first agent of the two-agent type permanent wave processing agent. It is desirable to add it to the drug for dilution in such an amount that it can be adjusted.

  In addition, there is no restriction | limiting in particular about the pH of this 1st agent, Although alkaline about pH 9 may be sufficient, Preferably it is pH 2.5-8.7, More preferably, it is pH 3.5-8.0, Most preferably, it is pH 4.0. It is desirable to be in the range of ~ 7.5. In addition, although the 1st agent of this 2 agent type permanent wave processing chemical | medical agent is effective even if it is alkaline, the effect becomes so large that it becomes neutral and weakly acidic.

  Examples of swelling agents and penetration enhancers include ethanol, propanol, isopropanol, 1,2-propylene glycol, dipropylene glycol, 3-methoxy-3-propanol, 1,3-butanediol, glycerin, ethyl carbitol, benzyl alcohol, Examples include benzyloxyethanol, urea, benzylamine, and 2-methylpyrrolidone.

  The surfactant may be anionic, cationic, amphoteric or nonionic, and may be a silicone surfactant or a biosurfactant. Examples of such surfactants include known ones.

For example, anionic surfactants include fatty acid salts, alkylbenzene sulfonates, alkyl naphthalene sulfonates, alkyl sulfonates, α-olefin sulfonates, dialkyl sulfosuccinate esters, disodium alkylamidoethyl sulfosuccinates. , Α-sulfonated aliphatic alkyl ester salts, sodium N-methyl-N-oleyl taurine, sodium alkyl isethinate, petroleum sulfonate, alkyl sulfate, sulfated oil, polyoxyethylene alkyl ether sulfate, poly Oxyethylene alkyl phenyl ether sulfate, polyoxyethylene styrenated phenyl ether sulfate, alkyl phosphate, polyoxyethylene alkyl ether phosphate, polyoxyethylene alkyl phenyl ether phosphate, poly Carboxymethyl ethylene alkyl ether methyl carboxylates, and naphthalene sulfonate formalin condensates and the like.

  Nonionic surfactants include polyoxyethylene alkyl ether, polyoxyethylene alkyl phenyl ether, polyoxyethylene polyoxypropylene glycol, polyoxyethylene polyoxypropylene alkyl glycol, polyhydric alcohol fatty acid partial ester, polyoxyethylene Ethylene polyhydric alcohol fatty acid partial ester, polyoxyethylene fatty acid mono (di) ester, polyglycerin fatty acid ester, polyoxyethylenated castor oil, fatty acid dietenol amide, polyoxyethylene alkylamine, triethanolamine fatty acid partial ester, trialkylamine Examples include oxides.

  Cationic surfactants include primary to tertiary fatty amine salts, tetraalkylammonium salts, trialkylbenzylammonium salts, alkylpyridinium salts, 2-alkyl-1-alkyl-1-hydroxyethylimidazolinium salts, N , N-dialkylmorpholinium salts, polyethylene polyamine fatty acid amide salts, salts of polyethylene polyamine fatty acid amide urea condensates, quaternary ammonium salts of polyethylene polyamine fatty acid amide urea condensates, oxo acid salts, fatty acids Examples thereof include salts.

Zwitterionic surfactants include N, N-dimethyl-N-alkyl-N-carboxymethylammoniobetaine, N, N, N-trimethyl-N-alkyleneammoniocarboxybetaine, N-acylamidopropyl-N ', N'-dimethyl-N'-β-hydroxypropylene ammoniosulfobetaine, N, N-dialkyl-N, N-bis (polyoxyethylenesulfuric acid) ammoniobetaine, 2-alkyl-1-hydroxyethyl-1 -Carboxymethylimidazolium betaine etc. are illustrated.

  Silicone surfactants include aminoethylaminopropylmethicone / dimethicone copolymer, amino-modified silicon such as amodimethicone, methylpolysiloxane, methylphenylpolysiloxane, dimethicone copolyol (polyoxyethylene / methylpolysiloxane copolymer), etc. Is mentioned.

  An example of a biosurfactant is a sodium salt of surfactin. Surfactin is composed of a hydrophilic part of a cyclic peptide consisting of 7 molecules of amino acid and a hydrophobic part of a long fatty acid residue. There are two carboxyl groups at both ends of the ring. Have a charge. The cyclic peptide contains two molecules of D-leucine, and L-leucine may be substituted with L-valine or L-isoleucine. Further, the chain length and branching position are appropriately selected for the fatty acid.

Examples of the buffer include inorganic buffers and buffers containing basic amino acids such as arginine and lysine.
Examples of the oil include paraffin, liquid paraffin, beeswax, squalane, jojoba oil, olive oil, ester oil, triglyceride, petrolatum, lanolin and the like.

  Thickeners include carboxymethylcellulose, carboxyvinyl polymer, hydroxyethylcellulose, hydroxypropylcellulose, xanthan gum, carrageenan, alginate, pectin, tragacanth gum, lauryl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, behenyl alcohol, etc. Examples include higher alcohols, kaolin, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, undecyl acid, isostearic acid and other fatty acids, petrolatum, and the like.

Examples of the hair protecting component include hydrolysates such as collagen and keratin, and derivatives thereof.
As humectants or emulsifiers, glycerin, diglycerin, propylene glycol, dipropylene glycol, 1,3-butanediol, sorbitol, plant extract, vitamins, hyaluronate, chondroitin sulfate, cationic, anionic, amphoteric , Ether type such as nonionic surfactant and polyoxyethylene oleyl ether, polyoxyethylene stearyl ether, polyoxyethylene cetyl ether, polyoxyethylene octylphenyl ether, polyoxyethylene dodecylphenyl ether, polyoxyethylene nonyl ether Nonionic surfactant, dimethylpolysiloxane, methylphenylpolysiloxane, amino-modified silicone oil, alcohol-modified silicone oil, fluorine-modified silicone oil, Rieteru modified silicone oil, and silicone derivatives, such as alkyl-modified silicone oil.

Examples of the stabilizer include dithiodiglycolic acid and the like in addition to the disulfide of the reducing compound for the purpose of preventing excessive reduction.
Examples of other additives include edetic acid and its metal salt, glutamic acid 4 acetic acid and its metal salt, aspartic acid 4 acetic acid and its metal salt, propyldiamine tetraacetic acid and its metal salt as chelating agents.

Further, the diluting drug is used in an amount within the range that does not impair the effects of the present invention, as well as conventionally known keratin reducing substances such as sulfite and bisulfite, thioglycolic acid and monoglycerol esters thereof. Thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine, and salts thereof may be used in combination.
<Method for preparing first agent of dual agent permanent wave processing agent>
The preparation method of the first agent of the two-part permanent waving agent of the present invention is such that the reducing agent-containing agent and the diluting agent are mixed in advance before being applied to the hair and used for the two-part permanent waving process. It is characterized by obtaining a first drug.

  That is, the reducing agent-containing drug containing the specific cyclic mercapto compound and the diluting drug containing water are not brought into contact with each other immediately before use, but are filled in containers as separate agents, and these are mixed at the time of use. Thus, the first agent of the two-agent type permanent wave processing chemical is obtained.

The mixing ratio between the reducing agent-containing drug and the diluent drug is preferably adjusted as appropriate according to the amount of the cyclic mercapto compound contained in the reducing agent-containing drug.
For example, the cyclic mercapto compound represented by the above formula (1) is contained 2% in terms of thioglycolic acid reducing power in the first agent of the two-component permanent wave processing agent finally obtained. May be prepared by mixing 94.8 g of the diluting drug with 5.2 g of the reducing agent-containing drug containing 50% by mass of the cyclic mercapto compound (containing 2.6 g of the cyclic mercapto compound). The order, conditions and method of mixing are not particularly limited, but from the viewpoint of convenience for the user, a method in which the entire amount of the reducing agent-containing drug and the diluting drug is used in a single preparation is used. It is desirable that the whole amount be simply mixed.

  There is no particular limitation on the form of the first agent of the resulting two-part permanent wave processing agent, and it may be in the form of a liquid, foam, gel, cream, paste, or the like. And according to the form, it can be used as various types of drugs such as liquid type, spray type, aerosol type, cream type and gel type.

Since the first agent of the two-part permanent wave processing agent contains the above-mentioned cyclic mercapto compound, it is excellent in the permanent wave processing performance of hair in a neutral to slightly acidic pH range with little irritation to the skin. ing.
<Preparation set for two-part permanent wave processing agent, permanent wave processing method for hair>
The two-part permanent wave processing chemical preparation set of the present invention comprises the above-mentioned first-part preparation set of the two-part permanent wave processing medicine composed of the reducing agent-containing medicine and the diluent, and an oxidizing agent. It is comprised from the 2nd agent of the chemical | medical agent for 2 agent type permanent wave processing to contain.

  As a 2nd agent of the chemical | medical agent for 2 agent type permanent wave processing containing an oxidizing agent, a well-known thing is mentioned. Specifically, for example, a commonly used aqueous solution of about 3 to 8% by mass of sodium bromate, or a dilute solution such as hydrogen peroxide or sodium perborate can be used.

The permanent wave processing method for hair according to the present invention is not particularly limited as long as it uses the above-mentioned preparation set for the two-component permanent wave processing agent. For example, a method for permanent wave processing for hair Examples of the method include the following steps (1) to (4). The permanent wave process includes a permanent wave forming process, a wave spreading process by a permanent wave process, and a hair straightening process.
(1) The first agent of the two-component permanent wave processing agent is prepared, wetted with hair, and wound with a rod for shaping the hair. Note that a rod is not used for straightening hair. Alternatively, the first agent may be moistened after fixing the hair with a water roll or the like.
(2) After the drug is wetted, it is left at room temperature. In that case, it is preferable to heat to about 30 to 40 degreeC.
(3) A cyclic mercapto compound is oxidized by a second agent of a two-part permanent wave processing agent containing an oxidizing agent to fix the hair.
(4) Remove the rod from the fixed hair, wash the hair, shampoo and dry.

  EXAMPLES Hereinafter, although this invention is demonstrated further more concretely based on an Example, this invention is not limited to these Examples.

[Synthesis Example 1]
Manufacture of 2-mercapto-4-butyrolactone 70% sodium hydrosulfide (49 g, 0.6 mmol, manufactured by Junsei Chemical Co., Ltd.) and methyl alcohol (500 g, Junsei Chemical Co., Ltd., special grade) and purified water (ion exchange filter after distillation) Water, 500 g). The dissolved liquid was cooled to 10 ° C. or lower under ice cooling while stirring. To the cooled solution, 2-bromo-4-butyrolactone (100 g, 0.6 mol, manufactured by Tokyo Chemical Industry Co., Ltd.) was added dropwise over about 30 minutes. After the completion of the dropwise addition, the liquid was stirred for 10 minutes, and then the reaction liquid was concentrated to about half volume under reduced pressure. To the concentrated liquid, ethyl acetate (500 mL, manufactured by Junsei Chemical Co., Ltd., special grade) was added for extraction. The resulting aqueous phase was re-extracted with ethyl acetate (500 mL). These extracted organic phases were combined, concentrated under reduced pressure, and purified by distillation to obtain 2-mercapto-4-butyrolactone (23 g, bp. 94 ° C./0.3 kPa, yield 32%).

[Reference Example 1]
Reactive agent-containing drug active ingredient residue rate evaluation test 2-mercapto-4-butyrolactone (hereinafter, also abbreviated as MBL) 2.6 g and the organic solvent 2.6 g shown in Table 1 are mixed to obtain a reducing agent-containing drug. Got. After filling the obtained reducing agent-containing drug into a 7 mL polyethylene container with a clear container weight (manufactured by Kaisei Kogyo Co., Ltd., SK-7), the container lid is opened and left standing upside down for 30 seconds. The contents were transferred to a beaker.

  Next, the weight of the emptied container (the weight of the container after the test) was measured, and the residual of 2-mercapto-4-butyrolactone was calculated from the measured value and the weight of the container before the filling (the weight of the container before the test) by the following formula. The rate was calculated. The calculation results are shown in Table 1.

Residual rate (%) = [(container weight after test−container weight before test) × 0.5] ÷ 2.6 × 100
[Reference Example 2]
Evaluation of residual ratio of active ingredient in reducing agent-containing drug Using 2-mercapto-4-butyrolactone as a reducing agent-containing drug, 2.6 g of a container with a lid made of 5 mL polyethylene with a clear container weight (manufactured by Kaisei Kogyo Co., Ltd., SK) After filling in 5), the lid of the container was opened, and the contents were left in an upside down state for 1 minute and transferred to a beaker.

  Next, the weight of the emptied container (the weight of the container after the test) was measured, and the residual of 2-mercapto-4-butyrolactone was calculated from the measured value and the weight of the container before the filling (the weight of the container before the test) by the following formula. When the rate was calculated, it was 13%.

  Residual rate (%) = [(container weight after test−container weight before test)] ÷ 2.6 × 100

  From Table 1, when a reducing agent-containing drug containing MBL and an organic solvent is used (Reference Example 1) as compared with the case where MBL is used as a reducing agent-containing drug in a stock solution (Reference Example 2), the container It can be seen that the amount of the active ingredient (MBL) remaining inside is decreasing. Therefore, the latter is easier to handle, and the MBL concentration adjustment in the first agent of the final two-agent permanent wave processing agent can be easily and reliably performed.

[Examples 1-7]
Permanent wave treatment was performed using the first agent of the following permanent wave processing agent and the second agent of the following permanent wave processing agent, and the influence on the permanent performance was confirmed. Preparation A of a first agent for permanent wave processing agent A solution (reducing agent-containing agent): 2.6 g of 2-mercapto-4-butyrolactone and 2.6 g of an organic solvent described in Table 2 in a 10 mL polyethylene lidded container A mixed solution.

  Liquid B (dilution agent): 88.8 g of purified water (water passed through an ion exchange filter after distillation) in a 100 mL polyethylene lidded container, 3 g of propylene glycol, 2 g of polyoxyethylene (20) cetyl ether, diphosphate A solution in which 0.2 g of sodium hydrogen and 0.8 g of disodium hydrogen phosphate were added and mixed so as to be uniform.

  The lid of the A liquid container was opened, and the contents were transferred to the container containing the B liquid by leaving it upside down for 30 seconds. Next, the lid of the container was closed, and the mixture was shaken for 30 seconds so that the liquid mixture of liquid A and liquid B was uniform, to obtain a first agent for permanent wave processing.

In addition, the content of 2-mercapto-4-butyrolactone in the first agent thus obtained corresponds to 2% in terms of thioglycolic acid reducing power. Further, Table 2 shows the pH of the first agent.
Preparation of second agent for permanent wave processing agent 5 g of sodium bromate and 95 g of purified water were mixed to obtain a second agent of permanent wave processing agent.
Permanent wave treatment wave efficiency was evaluated by the Kilby method according to the method described in the special issue of fragrance journal (1984, No. 5, page 442).

  First, Chinese hair (about 20 cm in length) was fixed to a Kilby instrument. The hair fixed to the first agent of the permanent wave processing agent heated to 33 ° C. was soaked for 20 minutes. After the treatment, it was wiped lightly so that the liquid did not drip from the hair taken out from the first agent. The second agent of the permanent waving agent was moistened on the hair and allowed to stand at 25 ° C. for 10 minutes. After the above treatment with the second agent was completed, the hair was washed with running water, the hair was removed from the kilbies and then the hair was dried. The dry hair thus obtained was measured, and the wave efficiency was calculated by the following wave efficiency calculation formula. The results are shown in Table 2.

Wave efficiency (%) = 100− [100 × (B−A)] ÷ (C−A)
A: Distance between the first and sixth rods of the kirby apparatus (actual measurement of the center point of the rods) (mm)
B: Length of 6 piles of curled hair (mm)
C: Length of 6 mountains when curled hair is straightened (mm)
[Example 8]
As a liquid A, a first agent of a permanent wave processing chemical was prepared in the same manner as in Examples 1 to 7, except that 2-mercapto-4-butyrolactone was used as a stock solution.

In addition, the content of 2-mercapto-4-butyrolactone in the first agent thus obtained corresponds to 2% in terms of thioglycolic acid reducing power.
The pH of the first agent was 5.9.

  Next, a second agent for permanent wave processing agent was prepared in the same manner as in Examples 1 to 7, except that the obtained first agent for permanent wave processing agent was used, and a permanent wave treatment was performed in the same manner. The wave efficiency was calculated. The results are shown in Table 2.

  From Table 2, compared to the case where MBL was used as a reducing agent-containing drug in the stock solution (Example 8), the case where the reducing agent-containing drug containing MBL and an organic solvent was used (Examples 1 to 7) However, it can be seen that the wave efficiency is more excellent. This is because the remaining amount of active ingredient contained in the reducing agent-containing drug in the container is smaller in the latter, so that the final adjustment of MBL concentration in the first drug of the dual-agent permanent wave processing drug is more reliably achieved. It is thought that it can be done.

Claims (11)

A first agent preparation set for a two-part permanent waving agent characterized by comprising a reducing agent-containing agent containing a compound represented by the following formula (1) and a diluting agent containing water;

(X represents a structure of any of —O—, —S—, —NH—, and —NR ¹ —. R ¹ represents an alkyl group having 1 to 6 carbon atoms. R ² represents a hydrogen atom or 1 carbon atom. Represents an alkyl group of ˜6, Y represents an oxygen atom or a sulfur atom, and R represents a divalent organic residue which may have a mercapto group.   The first agent preparation set for a two-component permanent wave processing agent according to claim 1, wherein the reducing agent-containing agent contains an organic solvent in addition to the compound represented by the formula (1). . The X of the formula (1) is —O—, —NH—, —NCH ₃ — or —S—, wherein the second agent for permanent wave processing according to claim 1 or 2 is used. One agent preparation set.   The Y agent of the formula (1) is an oxygen atom, The first agent preparation set for a two-agent permanent wave processing agent according to any one of claims 1 to 3.   R of said Formula (1) is an alkylene group, The 1st agent preparation set of the chemical | medical agent for 2 agent type permanent wave processing in any one of Claims 1-4 characterized by the above-mentioned.   5. The first preparation of a two-part permanent wave processing agent according to claim 1, wherein R in the formula (1) is an alkylene group having one or more mercapto groups. set. The compound represented by the formula (1) is
At least one selected from the group consisting of 2-mercapto-4-butyrolactone, 2-mercapto-4-methyl-4-butyrolactone, 2-mercapto-4-ethyl-4-butyrolactone and 2-mercapto-6-hexanolactam The first agent preparation set for a two-component permanent wave processing drug according to claim 1 or 2, wherein   The reducing agent-containing drug according to any one of claims 1 to 7 and the diluting drug are mixed in advance before being applied to the hair to obtain a first agent of a two-component permanent wave processing drug. The preparation method of the 1st agent of the chemical | medical agent for 2 agent type permanent wave processing to do.   A permanent wave processing method for hair, comprising using the first agent preparation set for the two-component permanent wave processing agent according to any one of claims 1 to 7.   It is comprised from the 1st agent preparation set of the chemical | medical agent for 2 agent type permanent wave processing in any one of Claims 1-7, and the 2nd agent of the agent for 2 agent type permanent wave processing containing an oxidizing agent. A preparation set of two-component permanent wave processing agents characterized by   A permanent wave processing method for hair, characterized in that the preparation set for a two-component permanent wave processing agent according to claim 10 is used.